Literature DB >> 10487844

A role for apoE in regulating the levels of alpha-1-antichymotrypsin in the aging mouse brain and in Alzheimer's disease.

F Licastro1, I L Campbell, C Kincaid, I Veinbergs, E Van Uden, E Rockenstein, M Mallory, J R Gilbert, E Masliah.   

Abstract

This study was designed to explore the possible functional relationships between apolipoprotein E (apoE) and the protease inhibitor alpha-1-antichymotrypsin in the aging mouse brain and in Alzheimer's disease. For this purpose, levels of EB22/5 (the mouse homologue to human alpha-1-antichymotrypsin) mRNA expression was studied in apoE-deficient mice. These mice showed an age-dependent increase of EB22/5 mRNA expression in the brain. Furthermore, overexpression of allele 3 of human APOE gene in transgenic mice (in an apoE-deficient background) resulted in normalization of levels of EB22/5 mRNA expression compatible with levels found in control mice. In contrast, overexpression of human APOE4 allele or down-regulation of the apoE receptor low density lipoprotein receptor-related protein by deletion of the receptor-associated protein was associated with elevated levels of EB22/5 similar to apoE-deficient mice. Consistent with the findings in murine models, human alpha-1-antichymotrypsin protein was increased in brain homogenates from patients with Alzheimer's disease, and levels of this serpin were the highest in patients with the APOE4 allele. In summary, the present study showed evidence supporting a role for apoE in regulating alpha-1-antichymotrypsin expression. This is relevant to Alzheimer's disease because these two molecules appear to be closely associated with the pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487844      PMCID: PMC1866911          DOI: 10.1016/s0002-9440(10)65186-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse.

Authors:  R Anderson; J C Barnes; T V Bliss; D P Cain; K Cambon; H A Davies; M L Errington; L A Fellows; R A Gray; T Hoh; M Stewart; C H Large; G A Higgins
Journal:  Neuroscience       Date:  1998-07       Impact factor: 3.590

2.  The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease.

Authors:  D Galasko; T Saitoh; Y Xia; L J Thal; R Katzman; L R Hill; L Hansen
Journal:  Neurology       Date:  1994-10       Impact factor: 9.910

3.  Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages.

Authors:  P Cullen; A Cignarella; B Brennhausen; S Mohr; G Assmann; A von Eckardstein
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

4.  Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins.

Authors:  Y Sun; S Wu; G Bu; M K Onifade; S N Patel; M J LaDu; A M Fagan; D M Holtzman
Journal:  J Neurosci       Date:  1998-05-01       Impact factor: 6.167

5.  Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments.

Authors:  J Ma; A Yee; H B Brewer; S Das; H Potter
Journal:  Nature       Date:  1994-11-03       Impact factor: 49.962

6.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.

Authors:  I L Campbell; C R Abraham; E Masliah; P Kemper; J D Inglis; M B Oldstone; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

7.  Altered long-term potentiation in the hippocampus of apolipoprotein E-deficient mice.

Authors:  I Veinbergs; M W Jung; S J Young; E Van Uden; P M Groves; E Masliah
Journal:  Neurosci Lett       Date:  1998-06-19       Impact factor: 3.046

8.  Apolipoprotein e4 allele and cognitive decline in elderly men.

Authors:  E J Feskens; L M Havekes; S Kalmijn; P de Knijff; L J Launer; D Kromhout
Journal:  BMJ       Date:  1994-11-05

Review 9.  Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease.

Authors:  J Poirier
Journal:  Trends Neurosci       Date:  1994-12       Impact factor: 13.837

10.  Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease.

Authors:  S Tanaka; X Chen; Y Xia; D E Kang; N Matoh; M Sundsmo; R G Thomas; R Katzman; L J Thal; J Q Trojanowski; T Saitoh; K Ueda; E Masliah
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

View more
  6 in total

1.  Expression patterns of murine antichymotrypsin-like genes reflect evolutionary divergence at the Serpina3 locus.

Authors:  Anita J Horvath; Sharon L Forsyth; Paul B Coughlin
Journal:  J Mol Evol       Date:  2004-10       Impact factor: 2.395

2.  Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation.

Authors:  Benjamin B Gelman; Kimberly Schuenke
Journal:  J Neurovirol       Date:  2004-04       Impact factor: 2.643

3.  Altered glycosylation profile of purified plasma ACT from Alzheimer's disease.

Authors:  Manuela Ianni; Marcella Manerba; Giuseppina Di Stefano; Elisa Porcellini; Martina Chiappelli; Ilaria Carbone; Federico Licastro
Journal:  Immun Ageing       Date:  2010-12-16       Impact factor: 6.400

4.  Serpin Signatures in Prion and Alzheimer's Diseases.

Authors:  Marco Zattoni; Marika Mearelli; Silvia Vanni; Arianna Colini Baldeschi; Thanh Hoa Tran; Chiara Ferracin; Marcella Catania; Fabio Moda; Giuseppe Di Fede; Giorgio Giaccone; Fabrizio Tagliavini; Gianluigi Zanusso; James W Ironside; Isidre Ferrer; Giuseppe Legname
Journal:  Mol Neurobiol       Date:  2022-04-13       Impact factor: 5.682

5.  Extracellular proteolysis of apolipoprotein E (apoE) by secreted serine neuronal protease.

Authors:  Irfan Y Tamboli; Dongeun Heo; G William Rebeck
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

6.  Alendronate Enhances Functional Recovery after Spinal Cord Injury.

Authors:  Yuna Choi; Taekyun Shin
Journal:  Exp Neurobiol       Date:  2022-02-28       Impact factor: 3.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.